( An ISO 9001:2015 Certified International Journal )

An International Peer Reviewed Journal for Pharmaceutical, Medical & Biological Sciences

An Official Publication of Society for Advance Healthcare Research (Reg. No. : 01/01/01/31674/16)

European Journal of Pharmaceutical and Medical Research (EJPMR) has indexed with various reputed international bodies like : Google Scholar , Indian Science Publications , InfoBase Index (In Process) , SOCOLAR, China , Research Bible, Fuchu, Tokyo. JAPAN , International Society for Research activity (ISRA) , Scientific Indexing Services (SIS) , Polish Scholarly Bibliography , Global Impact Factor (GIF) (Under Process) , Universal Impact Factor , International Scientific Indexing (ISI), UAE  , Index Copernicus , CAS (A Division of American Chemical Society) USA (Under Process) , Directory of Open Access Journal (DOAJ, Sweden, in process) , UDLedge Science Citation Index , CiteFactor , Directory Of Research Journal Indexing (DRJI) , Indian citation Index (ICI) , Journal Index (JI, Under Process) , Directory of abstract indexing for Journals (DAIJ) , Open Access Journals (Under Process) , Impact Factor Services For International Journals (IFSIJ) , Cosmos Impact Factor , Jour Informatics (Under Process) , Eurasian Scientific Journal Index (ESJI) , International Innovative Journal Impact Factor (IIJIF) , Science Library Index, Dubai, United Arab Emirates , Pubmed Database [NLM ID: 101669306] (Under Process) , IP Indexing (IP Value 2.40) , Web of Science Group (Under Process) , Directory of Research Journals Indexing , Scholar Article Journal Index (SAJI) , International Scientific Indexing ( ISI ) , Scope Database , Academia , 

 ISSN 2394-3211

Impact Factor: 7.065

 ICV - 79.57



Dr. Sharique Ahmad*, Dr. Ahmad Raza, Dr. Nishtha Bassi and Dr. Nishat I. Iram


Leucoreduction therapy, aimed at removing leukocytes from blood products before transfusion, has been extensively studied to evaluate its efficacy in clinical practice. This comprehensive review examines the impact of leucoreduction on patient outcomes, transfusion-related complications, and blood product safety. The review highlights the rationale behind leucoreduction and its mechanisms of action in reducing adverse reactions. It discusses the effectiveness of leucoreduction in mitigating febrile reactions, infections, transfusion-associated graft-versus-host disease, and alloimmunization. Furthermore, the review explores the safety aspects, including the impact on blood product quality and cost-effectiveness. Overall, leucoreduction therapy demonstrates effectiveness in reducing transfusion-related complications and improving blood product safety, with considerations for further research and optimization in different clinical settings. Leucoreduction therapy, also known as leukocyte reduction or leukodepletion, is a procedure aimed at removing leukocytes, primarily white blood cells, from blood products before transfusion. This comprehensive review evaluates the efficacy of leucoreduction therapy in clinical practice, focusing on its impact on patient outcomes, transfusion-related complications, and overall blood product safety. The review begins by examining the rationale behind leucoreduction therapy, which includes mitigating adverse reactions associated with transfusions, such as febrile non-haemolytic reactions, alloimmunization, and transfusion-related acute lung injury (TRALI). It explores the mechanisms by which leukocytes contribute to these complications, emphasizing the immunological and inflammatory processes involved. The impact of leucoreduction on clinical outcomes is extensively discussed, incorporating findings from numerous studies across different patient populations and medical settings. The review addresses the effectiveness of leucoreduction in reducing febrile reactions, infection rates, transfusion-associated graft-versus-host disease (TA-GVHD), and alloimmunization. Additionally, it evaluates the role of leucoreduction in preventing TRALI, a severe pulmonary complication associated with transfusions. Furthermore, the review examines the safety of leucoreduced blood products by analysing the potential risks and benefits of the procedure. It explores the impact of leucoreduction on blood product quality, including red blood cell and platelet function, as well as the potential for increased storage lesions and decreased shelf life. The impact on the availability and cost-effectiveness of leucoreduced blood products is also addressed. The comprehensive analysis reveals that leucoreduction therapy is effective in reducing the incidence of transfusion-related complications, particularly febrile reactions, alloimmunization, and TRALI. However, its impact on infection rates remains inconclusive. While there are concerns regarding storage lesions and increased cost, the overall safety and availability of leucoreduced blood products are acceptable for clinical use. In conclusion, this comprehensive review provides valuable insights into the efficacy of leucoreduction therapy in clinical practice. Leucoreduction demonstrates significant benefits in reducing transfusion-related complications, enhancing patient safety, and improving the overall quality of blood products. Nonetheless, further research is warranted to address remaining uncertainties and optimize the implementation of leucoreduction strategies in different clinical settings.

Keywords: Leucoreduction Therapy, Leukodepletion, Transfusion-Related Complications, Alloimmunization, Transfusion-Related Acute Lung Injury (TRALI)

[Full Text Article] [Download Certificate]


  All Since 2019
 Citation  3086  2560
 h-index  18  17
 i10-index  64  44



  • New Issue Published

    Its Our pleasure to inform you that, EJPMR 1 July 2024 Issue has been Published, Kindly check it on


    JULY 2024 issue has been successfully launched on JULY 2024.

  • EJPMR New Impact Factor

    EJPMR Impact Factor has been Increased to 7.065 for Year 2024.

  • Index Copernicus Value

    EJPMR Received Index Copernicus Value 79.57, due to High Quality Publication in EJPMR at International Level

  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.


  • Article Invited for Publication

    Article are invited for publication in EJPMR Coming Issue

Google Scholar Indian Science Publications InfoBase Index (In Process) SOCOLAR, China Research Bible, Fuchu, Tokyo. JAPAN International Society for Research activity (ISRA) Scientific Indexing Services (SIS) Polish Scholarly Bibliography Global Impact Factor (GIF) (Under Process) Universal Impact Factor International Scientific Indexing (ISI), UAE Index Copernicus CAS (A Division of American Chemical Society) USA (Under Process) Directory of Open Access Journal (DOAJ, Sweden, in process) UDLedge Science Citation Index CiteFactor Directory Of Research Journal Indexing (DRJI) Indian citation Index (ICI) Journal Index (JI, Under Process) Directory of abstract indexing for Journals (DAIJ) Open Access Journals (Under Process) Impact Factor Services For International Journals (IFSIJ) Cosmos Impact Factor Jour Informatics (Under Process) Eurasian Scientific Journal Index (ESJI) International Innovative Journal Impact Factor (IIJIF) Science Library Index, Dubai, United Arab Emirates Pubmed Database [NLM ID: 101669306] (Under Process) IP Indexing (IP Value 2.40) Web of Science Group (Under Process) Directory of Research Journals Indexing Scholar Article Journal Index (SAJI) International Scientific Indexing ( ISI ) Scope Database Academia